0, No. 6 May 2020 | Telemedicine and e-Health, Vol.
This can happen when a cyst is aspirated or when the specimen is almost entirely composed of blood.
SFN is preferred by some laboratories because a significant proportion of cases (up to 35%) prove not to be neoplasms but rather hyperplastic proliferations of follicular cells, most commonly those of multinodular goiter (The 2017 BSRTC includes a modification to the definition and diagnostic criteria for this category in light of NIFTP. Classification de Bethesda Classification internationale qui a permis de standardiser les critères diagnostiques et la prise en charge des nodules thyroïdiens Elle reconnait six catégories cytologiques qui sont associées à un risque de malignité spécifique pour chacune d’entre
Examples include specimens with obscuring blood, poor cell preservation, and an insufficient sample of follicular cells. Epub 2014 Sep 2.Eissa MS, Abdellateif MS, Elesawy YF, Shaarawy S, Al-Jarhi UM.Cancer Manag Res.
I. NONDIAGNOSTIC OR UNSATISFACTORY Cyst fluid only Virtually acellular specimen Other (obscuring blood, clotting artifact, etc.) Atypon
There is a choice of two different names for some of the categories. Each category has an implied cancer risk that ranges from 0% to 3% for the "benign" category to virtually 100% for the "malignant" category, and, in the 2017 revision, the malignancy risks have been updated based on new (post 2010) data.
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. Published by Elsevier Inc. All rights reserved.ScienceDirect ® is a registered trademark of Elsevier B.V.
The original TBSRTC recommended that an effort be made to limit its use to approximately ≤7% of all thyroid FNAs. La ponction du nodule , guidée par l'échographie va permettre de retirer des cellules et de les analyser au microscope par un médecin pathologiste. (v) The definition and diagnostic criteria for the papillary thyroid carcinoma subset of the malignant category have been modified to suggest limiting use to cases with “classical” features of papillary thyroid carcinoma. The 2017 Bethesda System for Reporting Thyroid Cytopathology Edmund S. Cibas1 and Syed Z. Ali2 The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. Surgically resected nodules, however, are a selected subset that were either repeatedly ND/UNS or had worrisome clinical/sonographic features or both. The 2017 BSRTC recommends subclassification of the atypia, even though this will not generally affect patient management.
The minimum requirement for group size allows one to determine (by the evenness of the nuclear spacing) whether it represents a fragment of a macrofollicle.Given that the great majority of ND/UNS nodules prove to be benign, one may question whether the criteria for adequacy are too stringent. A laboratory should choose the one it prefers and use it exclusively for that category.
There is a choice of two different names for some of the categories: a laboratory should choose the one it prefers and use it exclusively for that category; synonymous terms (eg, AUS and FLUS) should not be used to denote 2 distinct interpretations.
Inadequate samples are reported as “nondiagnostic” (ND) or “unsatisfactory” (UNS). The 2017 revision reaffirms that every thyroid FNA report should begin with one of six diagnostic categories, the names of which remain unchanged since they were first introduced: (i) nondiagnostic or unsatisfactory; (ii) benign; (iii) atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS); (iv) follicular neoplasm or suspicious for a follicular neoplasm; (v) suspicious for malignancy; and (vi) malignant. Atypon
A laboratory should choose the one it prefers and use it exclusively. As a function of their risk associations, each category is linked to updated, evidence-based clinical management recommendations. An inspiration for the thyroid proposal was the Bethesda System for reporting cervical cytology inter-pretations, first developed at an NCI workshop in 1988 and Ce dernier va classer le prélèvement dans l'une des 6 catégories de la classification Bethesda en fonction du risque … The Bethesda System for Reporting Thyroid Cytopathology, 2017 Laila Khazai 11/4/17 II.
The 2017 revision reaffirms that every thyroid FNA report should begin with one of six diagnostic categories, the names of which remain unchanged since they were first introduced: (i) nondiagnostic or unsatisfactory; (ii) benign; (iii) atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS); (iv) follicular neoplasm or suspicious for a follicular neoplasm; (v) suspicious for malignancy; and (vi) malignant. COVID-19 is an emerging, rapidly evolving situation.
Epub 2020 Apr 30.Fortuna GMG, Rios P, Rivero A, Zuniga G, Dvir K, Pagacz MM, Manzano A.J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620942672. doi: 10.1177/2324709620942672.
A laboratory should choose the one it prefers and use it exclusively for that category. Classification de Bethesda Classification internationale qui a permis de standardiser les critères diagnostiques et la prise en charge des nodules thyroïdiens Elle reconnait six catégories cytologiques qui sont associées à un risque de malignité spécifique pour chacune d’entre AUS/FLUS nodules with a benign repeat aspiration and/or a benign molecular test result remain (appropriately) unresected. Lowering the required number of follicular cells would save many patients a repeat FNA.